Claire Bugos

3 weeks ago | verywellhealth.com | Claire Bugos |Nick Blackmer

A daily GLP-1 pill can help people with type 2 diabetes regulate their blood sugar and lose weight, drugmaker Eli Lilly announced on Thursday. The readout comes just days after Pfizer announced it would abandon its own oral GLP-1 drug candidate due to worrying side effects. The drug, called orforglipron, helped people lose an average of 8% of their body weight after 40 weeks and lowered their A1C, a measure of blood sugar.

3 weeks ago | verywellhealth.com | Claire Bugos |Nick Blackmer

Zepbound supports sustained weight loss for up to three years among adults with obesity and overweight who don’t have diabetes, according to a study presented this week at the European Congress on Obesity in Spain. One study showed that people taking tirzepatide—the active ingredient in Zepbound—maintained weight loss for up to three years regardless of their age, body mass index (BMI), and or how long they had been living with obesity at the start of the study.

1 month ago | verywellhealth.com | Claire Bugos

People using GLP-1 drugs to manage their weight may be more likely to develop acne, according to a recent report. In a retrospective study, researchers analyzed the number of acne vulgaris diagnoses among people with obesity but not diabetes who had been prescribed Saxenda (liraglutide), Wegovy (semaglutide), or Zepbound (tirzepatide). The researchers matched more than 162,000 GLP-1 drug users—three-quarters of whom were women—with people who were not taking the medications.

1 month ago | verywellhealth.com | Claire Bugos |Nick Blackmer

As women age, their bodies transform. Fat more easily settles in their midsection. They tend to process calories slower and exercise less. Some of these changes happen as a natural part of aging, while others are related to shifts in sex hormones during the menopausal transition. Bodily changes during the menopause transition increase the risk of metabolic conditions such as obesity and diabetes.

1 month ago | verywellhealth.com | Claire Bugos

Genetic testing company 23andMe filed for bankruptcy in the United States on Sunday, raising concerns about the fate of highly sensitive genetic data from its 15 million customers. The company, best known for its at-home DNA testing kits, said it would continue to operate and would not change the way it protects consumer data while in bankruptcy court. Co-founder Anne Wojcicki stepped down as CEO this week and will attempt to buy the company back.